Group 1 - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%, driven by rising market prices of biological assets and natural growth appreciation [1] - Kaiyin Technology has withdrawn its drug registration application for Peginterferon α-2 injection, resulting in a one-time asset impairment of 110 million yuan, significantly impacting its 2025 profit [2] - Qizheng Tibetan Medicine's subsidiary has received approval for its Shiwai Longdan Flower Capsule as a national second-level protected traditional Chinese medicine, providing a seven-year market exclusivity that will enhance its competitive position [3] Group 2 - GSK has reached a final agreement to acquire RAPT Therapeutics, focusing on innovative therapies for inflammation and immune diseases, with the deal expected to close in Q1 2026 [4] - Qilu Pharmaceutical has initiated a Phase I clinical trial for QLS5316, its first dual-target antibody-drug conjugate aimed at advanced solid tumors, marking a significant step in its innovation strategy [5]

Core Viewpoint - The company Zhaoyan New Drug (603127.SH, 06127.HK) is expected to achieve a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, representing a year-on-year increase of about 214.0% to 371.0% despite a projected revenue decline of 13.9% to 22.1% [3][4]. Group 1: Financial Performance - Zhaoyan New Drug anticipates a revenue of 1.573 billion to 1.738 billion yuan for 2025, which reflects a year-on-year decrease [3]. - The significant increase in net profit is primarily attributed to changes in the fair value of biological assets rather than revenue growth [3][4]. - The rise in fair value is driven by an increase in market prices of biological assets and natural growth, contributing positively to the company's performance [3]. Group 2: Biological Assets - The biological assets referred to by Zhaoyan New Drug mainly consist of experimental monkeys, which are crucial for preclinical evaluations of drugs [4]. - Over 70% of large molecule drugs require monkeys for preclinical trials, and approximately 20%-30% of small molecule chemical drugs also utilize them [4]. - The price of experimental monkeys is closely linked to the innovation and development of new drugs, with prices having fluctuated significantly in recent years [5]. Group 3: Market Dynamics - Following the COVID-19 pandemic, the demand for experimental monkeys surged, leading to prices exceeding 200,000 yuan per monkey in 2022, but prices fell below 100,000 yuan in 2023 due to reduced R&D spending by pharmaceutical companies [5]. - As the pharmaceutical capital market recovers and domestic innovative drugs gain traction, the price of experimental monkeys is expected to rise again, surpassing 100,000 yuan each in 2025 [5][6]. - The current market conditions indicate a supply-demand imbalance for experimental monkeys, with prices for 3-5 year old monkeys reaching 140,000 yuan each, reflecting a recovery in the domestic innovative drug development landscape [6].

Industry Overview - The Chinese clinical CRO industry is entering a recovery and stable growth phase, transitioning from an offshore outsourcing model to a global contributor of innovative assets over the past decade [2][13] - The industry experienced a growth phase from 2017-2019 and a rapid development period from 2020-2022, with a forecasted compound annual growth rate (CAGR) of over 12% from 2025 to 2028, expecting to exceed 75 billion RMB by 2028 [2][13] - As of December 2025, the average number of clinical trial projects undertaken by each clinical CRO in China increased by 20.6% year-on-year, reaching 42.9 projects, narrowing the gap with the U.S. [5][16] Investment Trends - The investment from multinational pharmaceutical companies in China's clinical trials remains stable, with 25%-30% of Phase III innovative drug trials initiated by these companies over the past eight years [6][17] - Local pharmaceutical companies are also actively investing in innovative drug clinical research, contributing 15%-20% of Phase III trials in China during the same period [6][17] - The financing channels for Chinese innovative drugs have diversified, with a significant increase in licensing and mergers and acquisitions (M&A) transactions, totaling 178 deals in 2024-2025 [9][20] Company Highlights - Tigermed has ranked first in market share in China's clinical CRO sector for several years, with a compound annual growth rate of 14.8% in new orders from 2019 to 2024, surpassing the market's growth rate of 12.5% [11][23] - The average price of domestic clinical trial services is stabilizing after fluctuations in 2022-2023, indicating strong business continuity and resilience [11][23] - In 2025, Tigermed aims for sustainable development, achieving an AAA rating in MSCI ESG, and enhancing its service capabilities through the acquisition of CRO company Micron [11][23] - The company is investing in AI applications and platforms, launching an AI medical translation platform and an AI medical writing platform in 2025 [11][23]

Group 1 - The core viewpoint of the news is that Zhaoyan New Drug (昭衍新药) is expected to achieve a significant increase in net profit for 2025, despite a decline in revenue, primarily driven by the fair value changes of biological assets, particularly experimental monkeys [1][2]. - The company forecasts a net profit attributable to shareholders of approximately 233 million to 349 million yuan for 2025, representing a year-on-year increase of about 214.0% to 371.0% [1]. - Zhaoyan New Drug anticipates revenue between 1.573 billion and 1.738 billion yuan for 2025, which reflects a year-on-year decline of 13.9% to 22.1% [1]. Group 2 - The company’s biological assets, mainly consisting of experimental monkeys, have seen a price increase due to rising market prices and natural growth, contributing positively to its performance [1][2]. - The price of experimental monkeys is closely linked to the innovation drug development climate, with prices having fluctuated significantly in recent years, peaking at over 200,000 yuan per monkey during the COVID-19 pandemic and dropping below 100,000 yuan in 2023 [2]. - As of 2025, the price of experimental monkeys is expected to rise again, surpassing 100,000 yuan each, driven by a recovery in the pharmaceutical capital market and increased licensing of domestic innovative drugs [2][3]. Group 3 - Zhaoyan New Drug's performance has experienced volatility in line with the fluctuations in experimental monkey prices, indicating a correlation between the demand for experimental monkeys and the recovery of the innovative drug development sector [3]. - Current market conditions show that the price of 3-5 year old experimental monkeys has risen to 140,000 yuan each, with a supply-demand imbalance indicating a recovery in the domestic innovative drug research and development environment [3].

Investment Rating - The report gives a "Strong Buy" rating for the company, marking its first coverage [3]. Core Insights - The company is transitioning into a new phase characterized by innovation and internationalization, with a focus on commercializing innovative drugs and expanding into emerging markets [1][7]. - The impact of centralized procurement on core products is expected to stabilize, leading to a recovery in revenue and profit growth starting in 2024 [7][13]. - The company has a robust pipeline of nearly 40 innovative drug candidates, with several expected to launch commercially in 2024 [7][23]. Financial Data and Valuation - Total revenue is projected to decline from 8,013 million in 2023 to 7,469 million in 2024, before increasing to 10,061 million by 2026 [2]. - Net profit is expected to decrease from 2,401 million in 2023 to 1,620 million in 2024, with a recovery to 1,955 million by 2026 [2]. - The company’s PE ratio is forecasted to improve from 18.6 in 2024 to 15.4 in 2026, indicating a potential increase in valuation [2]. Business Model and Strategy - The company has evolved from a CSO model to a full-chain innovative pharmaceutical enterprise, focusing on specialized fields such as dermatology and ophthalmology [11][18]. - The internationalization strategy includes expanding into Southeast Asia and the Middle East, with nearly 20 drug applications submitted in these regions [7][11]. - The company plans to spin off its dermatology business, Demy Pharma, for independent listing, enhancing its focus on specialized markets [7][11]. Product Pipeline and Market Potential - The innovative product pipeline includes five drugs that have already been commercialized, with additional candidates in various stages of development [20][24]. - Key products such as Vifor (for chronic kidney disease) and Y-3 (for acute ischemic stroke) are expected to drive future growth [29][37]. - The company is targeting significant unmet medical needs in the Chinese market, particularly in areas like high phosphorus levels in dialysis patients and rabies passive immunity [31][47].

Core Viewpoint - The company, Xiansheng Zaiming Pharmaceutical Co., Ltd., has submitted an IPO application to the Hong Kong Stock Exchange, aiming to establish a dedicated financing platform for its oncology business, which is currently under the parent company, Xiansheng Pharmaceutical [1][8]. Financial Performance - The company reported revenues of 1.522 billion yuan, 1.296 billion yuan, and 1.238 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively [2]. - Despite stable revenue growth, the company remains in a loss position due to high R&D and sales expenses, recording net losses of 336 million yuan, 506 million yuan, and 303 million yuan for the same periods [6]. - R&D costs were 831 million yuan, 708 million yuan, and 512 million yuan for 2023, 2024, and the first nine months of 2025, with R&D expenses exceeding 50% of revenue in 2023 and 2024 [5]. Business Strategy - The company focuses on the development and commercialization of innovative oncology drugs, having five commercialized products that contribute over 90% of total revenue [4]. - The split from Xiansheng Pharmaceutical allows the company to optimize its financial structure while maintaining absolute control over the oncology business [2]. - The company has established a sales and marketing team of over 1,200 people to enhance product marketization [5]. Market Position and Collaborations - Xiansheng Zaiming has engaged in multiple licensing collaborations with companies like AbbVie, Ipsen, and NextCure, with a potential total transaction value exceeding 2.8 billion USD [5]. - The company ranks first in the number of oncology asset transactions and fourth in total value among Chinese biopharmaceutical companies [5]. Challenges and Considerations - The company faces challenges related to high market channel concentration, with the top five customers accounting for over 65% of revenue [11]. - The overall gross margin has decreased from approximately 72% to 68.1%, attributed to structural adjustments in revenue sources and product mix [12]. - The company has set a timeline for its IPO process, needing to submit its application by June 2027 and complete the listing by the end of 2028, with penalties for delays [12].

Market Overview - The Hong Kong stock market experienced a decline on January 19, with the Hang Seng Index falling by 0.76% [1] - The pharmaceutical sector faced significant losses, particularly in the innovative drug industry, with major stocks like Alibaba Health and others in the AI medical concept continuing to drop [1][10] Innovative Drug Sector Performance - The innovative drug sector saw a broad adjustment, with leading companies experiencing declines: China Biologic Products fell by 6.19%, CanSino Biologics by 3%, and others like Innovent Biologics and Hansoh Pharmaceutical dropped over 4% [1][13] - The Hong Kong Stock Connect Innovative Drug ETF (520880) fell by 2.72%, marking a three-day losing streak and losing both the 10-day and 60-day moving averages, with trading volume increasing by over 50% to 390 million HKD [11][12] Factors Influencing Market Sentiment - The adjustments in the innovative drug sector are attributed to the market digesting sentiments post the JPMorgan Healthcare Conference, which concluded on January 15, and a cautious outlook ahead of upcoming earnings forecasts for 2025 [4][15] - The market is currently in a phase of waiting for actual revenue and profit data, leading to a tendency to avoid uncertainty, particularly for companies that are not yet profitable or are in the early stages of commercialization [4][15] Future Outlook for Innovative Drug Sector - The innovative drug sector is expected to see significant earnings forecasts from leading companies in 2025, which could present opportunities for valuation recovery if results exceed expectations [5][16] - The sector's long-term fundamentals remain strong, with projections indicating that the total overseas licensing revenue for innovative drugs could reach 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [16] - Continued policy support is anticipated, with the National Medical Products Administration expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the review and approval processes [16] Investment Strategy - The Hong Kong Stock Connect Innovative Drug ETF (520880) is positioned as a high-elasticity T+0 investment tool, focusing exclusively on innovative drug R&D companies [5][16] - The ETF's index features a significant concentration of leading companies, with the top ten holdings accounting for over 73% of the total weight, indicating a strong representation of the sector's core strengths [6][17]

Core Viewpoint - QianYuan Pharmaceutical has initiated research on innovative drug projects targeting anti-aging and weight loss, with plans to increase investment and accelerate the development of its drug pipeline [2] Group 1 - QianYuan Pharmaceutical has launched two innovative drug research pipelines focused on anti-aging and weight loss [2] - The company plans to increase the number of pipelines and accelerate the progress of innovative drug development in the future [2]

Investment Rating - The report indicates a positive investment outlook for the TCE therapy in multiple myeloma, particularly highlighting the success of teclistamab in clinical trials [13][14][17]. Core Insights - The report emphasizes the significant advancements in TCE therapies for multiple myeloma, particularly the promising results from the MajesTEC-9 trial, which demonstrated a 71% reduction in disease progression or death risk and a 40% reduction in mortality risk for teclistamab compared to standard treatments [14][15]. - The report also notes the ongoing exploration of teclistamab in earlier treatment lines and in difficult-to-treat populations, indicating a potential shift in treatment paradigms for multiple myeloma [14][15]. Summary by Sections Section 1: Focus on Innovative Drugs - The report reviews the current landscape of innovative drugs in the market, particularly focusing on TCE therapies for hematological malignancies and their expansion into solid tumors [5][6]. Section 2: TCE Therapy Development in Multiple Myeloma - Multiple TCE therapies targeting BCMA and GPRC5D have received FDA approval for treating relapsed or refractory multiple myeloma, with overall response rates (ORR) ranging from 60% to 74% and median progression-free survival (PFS) of approximately one year [9][10]. - The report highlights the unmet medical needs in multiple myeloma, with a significant proportion of patients experiencing relapse and resistance to current therapies [9][10]. Section 3: Clinical Trial Results - The MajesTEC-9 trial results indicate that teclistamab significantly improves PFS and overall survival (OS) in patients who are resistant to prior therapies [14][15]. - The report details various clinical trials, including MajesTEC-3 and MajesTEC-5, which support the efficacy of teclistamab in combination with other therapies, showing high ORR and MRD-negative rates [21][25]. Section 4: Future Prospects - The report discusses the potential for TCE therapies to become standard treatment options in multiple myeloma, with ongoing trials exploring their use in earlier lines of therapy and in combination with other agents [14][25][28]. - The report also mentions the strategic partnerships and collaborations in the industry aimed at advancing TCE therapies, indicating a robust pipeline for future developments [35][36].

Core Insights - The Hong Kong Wealth Management Summit and the 12th Hong Kong Stock Top 100 Awards recognized Hansoh Pharmaceutical as an "Annual Medical Innovation Pioneer" and included it in the "Top 100 Comprehensive Strength" list, highlighting its status as a core benchmark for innovation in the Hong Kong pharmaceutical sector [1] Group 1: Company Performance - In the first half of 2025, Hansoh Pharmaceutical achieved revenue of 7.434 billion yuan, representing a year-on-year growth of 14.3%, with innovative drugs and collaborative product sales accounting for 82.7% of total revenue, serving as the main driver of growth [2] - The company has established four R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, employing over 1,900 specialized R&D personnel, thus creating a complete innovation system from compound screening to clinical research [2] Group 2: Global Expansion - Hansoh Pharmaceutical successfully obtained two marketing approvals for Amelot® in the UK, marking it as the first Chinese original third-generation EGFR-TKI to enter the mainstream European market, laying a solid foundation for future expansion into the EU [3] - The company announced a collaboration with Indian pharmaceutical company Glenmark for exclusive rights to Amelot® across multiple regions, with a total potential value exceeding 1 billion USD, further demonstrating its achievements in internationalization [3] - Hansoh has established a global innovation network through bilateral business development collaborations, having introduced 12 cooperative projects, with 10 entering clinical stages and 2 achieving commercialization, forming a dual innovation model of "independent R&D + external collaboration" [3] Group 3: Industry Context - The domestic innovative drug industry is entering a critical phase of "commercialization and global breakthrough," with policy support, explosive overseas transactions, and the emergence of profitability points creating vast opportunities for industry development [3] - Recognition as an "Annual Medical Innovation Pioneer" reflects the capital market's acknowledgment of Hansoh's past achievements and expectations for its future growth potential [3]